Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis
Albumin-bound paclitaxel plus S-1 with a PD-1 inhibitor and intraperitoneal or intravenous bevacizumab was well tolerated in gastric cancer patients with peritoneal metastasis.
Authors
- Tao Zhang (ORCID: https://orcid.org/0000-0001-7650-3980)
- Yuxi Ma (ORCID: https://orcid.org/0000-0003-4087-9219)
- Jianli Hu
- Yali Yang (ORCID: https://orcid.org/0000-0002-7912-9530)
- Yuting Li (ORCID: https://orcid.org/0009-0009-7987-6438)
- Jing Wang (ORCID: https://orcid.org/0000-0001-7199-4784)
- Hongli Liu (ORCID: https://orcid.org/0000-0002-2179-1468)
- Junli Liu (ORCID: https://orcid.org/0000-0001-9082-692X)
- Zhenyu Lin (ORCID: https://orcid.org/0000-0002-1733-5806)
Institutions
- Union Hospital (HK)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1186/s12885-025-14206-9
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China